EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

Stephen A Harrison, Vlad Ratziu iD, Quentin M Anstee iD, Mazen Noureddin, Arun J Sanyal iD, Jörn M Schattenberg iD, Pierre Bedossa, Mustafa R Bashir, David Schneider, Rebecca Taub, Meena Bansal, Kris V Kowdley und 2 weitere

Alimentary Pharmacology & Therapeutics · 2024-01 · 59 (1) · 51-63

DOI: 10.1111/apt.17734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 02.10.2023. Verfasst von Stephen A Harrison und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pinnacle Clinical Research Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Madrigal Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver‐targeted thyroid hormone receptor‐β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo.

Aims

To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO‐NAFLD‐1 [NCT04197479], MAESTRO‐NAFLD‐OLE [NCT04951219], MAESTRO‐NASH [NCT03900429], MAESTRO‐NASH‐OUTCOMES [NCT05500222]).

Methods

MAESTRO‐NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy‐confirmed at‐risk NASH. Patients are randomised to a once‐daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO‐NAFLD‐1 is a 52‐week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non‐invasive testing); ~700 patients from MAESTRO‐NAFLD‐1 are enrolled in MAESTRO‐NAFLD‐OLE, a 52‐week active treatment extension to further evaluate safety. MAESTRO‐NASH‐OUTCOMES is enrolling 700 adults with well‐compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non‐invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient‐reported outcomes.

Conclusion

The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long‐term clinical liver‐related outcomes in MAESTRO‐NASH (month 54) and MAESTRO‐NASH‐OUTCOMES (time to event).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAdultHumansLiverLiver CirrhosisBiomarkersRandomized Controlled Trials as TopicPyridazinesUracil

Substanzen

BiomarkersresmetiromPyridazinesUracil

Autor:innen und Institutionen

  • Pinnacle Clinical Research Center, San Antonio, Texas, USA.
  • Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Sorbonne University, Paris, France.
  • Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle-Upon-Tyne, UK.
  • Houston Research Institute, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.

ORCID-Profile: Vlad Ratziu, Quentin M Anstee, Arun J Sanyal, Jörn M Schattenberg, Zobair M Younossi

Förderung

  • Madrigal Pharmaceuticals

Zitieren

APA

Harrison, S. A., Ratziu, V., Anstee, Q. M., Noureddin, M., Sanyal, A. J., Schattenberg, J. M., Bedossa, P., Bashir, M. R., Schneider, D., Taub, R., Bansal, M., Kowdley, K. V., Younossi, Z. M., & Loomba, R. (2024). Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics, 59(1), 51-63. https://doi.org/10.1111/apt.17734

Vancouver

Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2024;59(1):51-63. doi:10.1111/apt.17734

BibTeX
@article{Harrison2024,
  author = {Harrison, Stephen A and Ratziu, Vlad and Anstee, Quentin M and Noureddin, Mazen and Sanyal, Arun J and Schattenberg, Jörn M and Bedossa, Pierre and Bashir, Mustafa R and Schneider, David and Taub, Rebecca and Bansal, Meena and Kowdley, Kris V and Younossi, Zobair M and Loomba, Rohit},
  title = {Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {1},
  pages = {51--63},
  doi = {10.1111/apt.17734}
}
Kostenlos starten →